DERMATA THERAPEUTICS INC

Company Overview

Dermata Therapeutics (DRMA) is a late-stage medical dermatology biotech developing Spongilla-based topical therapies. Its lead candidate, XYNGARI (Spongilla + 3% H2O2), reported positive Phase 2 data and met co-primary endpoints in the STAR‑1 Phase 3 topline announced March 2025, but the FDA has requested a second Phase 3 (STAR‑2) plus a 12‑month extension and additional toxicology. A second program, DMT410, uses Spongilla to create dermal microchannels for macromolecule delivery and has shown encouraging Phase 1b signals in hyperhidrosis and aesthetic indications. The company has no product revenue, relies on a single seasonal raw‑material supplier and contract manufacturers, is small (≈8 FTEs), and is runway‑constrained—recent financings extend cash into mid‑2026 but additional capital or partnerships are expected.

Executive Compensation Practices

Compensation at Dermata is likely highly milestone‑driven and skewed toward equity-based pay (stock options/RSUs) given the company’s pre‑revenue status, limited cash and small headcount—this aligns incentives to clinical, regulatory and partnership outcomes (e.g., STAR‑2 success, FDA acceptance, Revance collaboration milestones). As late‑stage costs rise (R&D and potential commercial readiness), management may receive retention awards or milestone bonuses tied to trial enrollment/endpoint achievement, NDA/label milestones, or licensing revenue; cash salaries are probably conservative relative to market, with greater reliance on long‑dated equity to conserve cash. Recent financing activity (PIPE, inducement financings and warrant arrangements) and the need to scale a specialty sales force if commercialized mean compensation plans may include deal‑contingent payments, change‑in‑control protections for executives, and performance vesting tied to fundraising or partnership milestones.

Insider Trading Considerations

Insider trading patterns at Dermata will likely cluster around clinical and regulatory milestones (e.g., STAR‑1/STAR‑2 toplines, FDA requests, toxicology updates) and financing events; insiders exercising options to cover taxes or participating in PIPEs/inducements have been evident historically and can create noisy trading signals. Given the small number of insiders and low float typical of early biotechs, even modest insider buys or sells can materially move the stock—insider purchases are more credible as a confidence signal, while sales may reflect option liquidity needs or dilution hedges. Expect routine use of Rule 10b5‑1 plans and common blackout periods ahead of major disclosures; watch filings around collaborations (e.g., Revance), supply agreements, and manufacturing milestones since those operational dependencies can trigger significant insider activity. Regulatory constraints (Section 16 reporting, FDA‑sensitive disclosure timing and confidentiality around ongoing trials) further shape when insiders may legally and reputationally transact.